Table 1. Clinical characteristics and baseline immune parameters.

	HIV-(n = 16)	HIV+/ART treated (n = 26)	P value
Age	38 (33-55)	43 (32-51)	0.87
Sex (male/female)	5/16 (31.3%)	17/26 (65.4%)	0.07
CD4+ T cell counts	771 (544-977)	540 (366-722)	0.03
%annexin V+ CD4	19.0 (13.0-40.0)	30.3 (19.8-38.5)	0.2
%CD38+ mCD4	14.3 (10.1-16.8)	18.4 (11.3-22.9)	0.33
%B cells in PBMC	7.7 (6.2-9.5)	9.3 (6.9-11.3)	0.25
16S rDNA (copie/μL)	5.3 (0-34.7)	18.2 (9.4-25.2)	0.18
Co-infection with HCV		2/26
Infection duration
2-5 years		5/26
5-10 years		3/26
> 10 years		18/26
AIDS-defining events
HIV associated malignancy		2/26
Opportunistic infections		4/26
Nadir CD4+ T cell counts		294 (193-458)
NNRTI based therapy		16/26
PI based therapy		10/26

Data are medians (interquartile ranges)

P value: comparisons of P value between controls and patients on D0